Daraxonrasib

KRAS-mutant solid tumors have long represented a clinical pain point in targeted oncology. Activating mutations in KRAS, NRAS, and HRAS occur in roughly 30% of all human cancers and serve as core drivers in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and a subset of non-small cell lung cancer. Conventional chemotherapy and immunotherapy have offered limited response in RAS-driven disease, and while the earlier allele-specific KRAS G12C inhibitors validated RAS as a druggable target, they left the majority of other RAS-mutant subtypes unaddressed—making pan-RAS targeting the next frontier. Daraxonrasib (development code RMC-6236) is an orally administered, small-molecule non-covalent RAS(ON) multi-selective inhibitor. Its mechanism differs fundamentally from that of conventional G12C covalent inhibitors: it forms a non-covalent "tri-complex" with the intracellular chaperone protein cyclophilin A and active, GTP-bound (ON-state) RAS, blocking RAS from engaging downstream effectors (RAF-MEK-ERK and related pathways) and thereby suppressing proliferative signaling. This approach covers multiple mutant forms—including KRAS G12D, G12V, G13D, and Q61X—as well as wild-type RAS isoforms, giving it a substantially broader target spectrum than single-allele G12C inhibitors. Its clinical development centers on previously treated metastatic pancreatic ductal adenocarcinoma harboring KRAS G12 mutations and on a range of RAS-driven advanced solid tumors (including NSCLC); the specific eligible population and guideline-recommended details remain to be confirmed.

The overall global market size for pan-RAS/RAS(ON) inhibitors remains to be confirmed, as do the recent compound annual growth rate, China end-market sales, market growth rate, and the status of reimbursement listing and centralized procurement. With respect to the competitive landscape, the originator's market share, the number of approved domestic generics, and the price reduction under national volume-based procurement all remain to be confirmed. As domestic pharmaceutical companies advance the development of Daraxonrasib generics and improved new drugs, demand for upstream APIs and accompanying impurity reference standards continues to grow.

The originator of Daraxonrasib is Revolution Medicines (USA); the originator brand name remains to be confirmed (the product had not been approved for marketing in China as of the data cutoff). The expiry year of the core compound patent in China remains to be confirmed. The principal dosage form is oral, with standard strengths to be confirmed; whether it is listed in China's Catalogue of Reference Listed Drugs for Chemical Drugs and whether it is designated as an FDA Reference Listed Drug both remain to be confirmed. On China's CDE API registration platform, the total number of registrations, the number of records in "A" status, and the corresponding approved dosage forms all remain to be confirmed. (Data as of June 2026; please refer to the official CDE website for the latest information.)

CATO provides a complete set of Daraxonrasib impurity reference standards, covering qualitative and quantitative needs for impurities across API development, quality research, and production. These standards support every stage of research, including generic bioequivalence/consistency evaluation and new drug registration filings. Most products are available from stock, with same-day shipment for in-stock items ordered before 16:00, and all reference standards comply with the Chinese Pharmacopoeia, FDA, and other multinational regulatory requirements—helping pharmaceutical companies maintain R&D and quality compliance.